PatientsVille.com Logo

VISUAL IMPAIRMENT and Oxycodone

PatientsVille

VISUAL IMPAIRMENT Symptoms and Causes

If you have low vision, eyeglasses, contact lenses, medicine, or surgery may not help. Activities like reading, shopping, cooking, writing, and watching TV may be hard to do. The leading causes of low vision and blindness in the United States are age-related eye diseases: macular degeneration, cataract and glaucoma. Other eye disorders, eye injuries, and birth defects can also cause vision loss.

Whatever the cause, lost vision cannot be restored. It can, however, be managed. A loss of vision means that you may have to reorganize your life and learn new ways of doing things. If you have some vision, visual aids such as special glasses and large print books can make life easier. There are also devices to help those with no vision, like text-reading software and braille books.

The sooner vision loss or eye disease is found and treated, the greater your chances of keeping your remaining vision. You should have regular comprehensive eye exams by an eye care professional.

NIH: National Eye Institute

Check out the latest treatments for VISUAL IMPAIRMENT

VISUAL IMPAIRMENT treatment research studies

Oxycodone clinical trials, surveys and public health registries


Find Drug Side Effect reports



Oxycodone Side Effects

Completed Suicide (541)
Respiratory Arrest (500)
Cardiac Arrest (472)
Toxicity To Various Agents (364)
Cardio-respiratory Arrest (309)
Nausea (300)
Poisoning (264)
Overdose (263)
Exposure Via Ingestion (248)
Vomiting (245)
Death (235)
Pain (219)
Somnolence (218)
Substance Abuse (199)
Confusional State (188)
Constipation (188)
Delirium (178)
Headache (164)
Dizziness (162)
Accidental Overdose (148)
Dyspnoea (110)
Anxiety (94)
Diarrhoea (87)
Fall (85)
Loss Of Consciousness (85)
Road Traffic Accident (85)
Depressed Level Of Consciousness (76)
Asthenia (74)
Hyperhidrosis (72)
Lethargy (72)
Abdominal Pain (71)
Coma (71)
Malaise (70)
Product Quality Issue (70)
Agitation (69)
Pruritus (68)
Depression (64)
Mental Status Changes (64)
Fatigue (63)
Insomnia (61)
Impaired Driving Ability (60)
Feeling Abnormal (59)
Unresponsive To Stimuli (57)
Product Substitution Issue (56)
Rash (55)
Pneumonia (54)
Inadequate Analgesia (54)
Back Pain (54)
Malignant Neoplasm Progression (50)
Dehydration (50)

➢ More


Common Meds

Abilify (10132)
Adderall (1304)
Amlodipine (6664)
Amoxicillin (4387)
Benadryl (1568)
Celebrex (12876 )
Celexa (1342)
Cialis (2975)
Cipro (8580)
Citalopram (7792)
Crestor (18839)
Cymbalta (14373)
Doxycycline (1757)
Effexor (7289)
Flexeril (435)
Flomax (2177)
Fluoxetine (4261)
Gabapentin (4593)
Hydrocodone (2469)
Ibuprofen (8222)
Lantus (10968)
Lexapro (3499)
Lipitor (17769)
Lisinopril (8919)
Lyrica (27148)
Medrol (650)
Mirena (41254)
Mobic (957)
Morphine (5356)
Naproxen (538)
Neurontin (6501)
Oxycodone (4438)
Pradaxa (13372)
Prednisone (5926)
Prilosec (2631)
Prozac (1954)
Seroquel (27216)
Simvastatin (8348)
Synthroid (4452)
Tamiflu (5585)
Topamax (3748)
Tramadol (5054)
Trazodone (1458)
Viagra (5394)
Vicodin (1153)
Wellbutrin (6324)
Xanax (2847)
Zocor (5718)
Zoloft(6792)
Zyrtec(1669)

Recent Reviews

I am searching for how oxycodone affects ascites.

<strong></strong><span style='text-decoration: underline;'>Have severe back and knee pain. One of the shots in my back worked and I got off oxycodone for a couple of weeks by taking

Depression of Pituitary function, requiring hormone replacement

I been taking oxycodone for months now and wanted to know about withdrawl

I was prescribed this medication after months of being on just oxycodone. I had major side effects from the naloxone. It made me very depressed and also gave me extreme migrane headaches. Also made my legs feel tracing pain and prevented me from slee

It seems i have to take to function on a daily

Itching

What's on your miRnd...im too tired on this new oxycontin, pain relie is not enough

<span style='color: #808080;'><b>What do You think about Vision impairment and blindness?</b>

49yo female, 2/7 days use. Dose 15mg daily, after food. Experiencing severe headaches, visual disterbances, intermittent confusion, visual dreams/ hallucinations, exhaustion.

After about one month on the monthly dosage of Actonel I experienced jaw pain, muscle and joint pain and visual disturbances. Doctor wants to put me on Boniva. I've already tried Fosomax which caused me to have difficulty swallowi

Does long times usage of Concor 5mg cause any function in my health like memory impairment ?

Ever since I was on Sensipar ive been getting Migraines.'Visual first then Migrain following

I am a 67 yr old female, was prescribed Istn in 1990, and had no problem until two years ago. I then started to experience quite severe side effects, headaches, dizziness, nausea, visual disturbances, fatigue, anxiety among others. Since then my doct

I experienced a severe visual impairment, white sparkling lights to point of sight loss, distorted audio , near loss of bodily functions, severe h/a, sweating, chest pains, taste of the medication? in my mouth, unable to respond or move. It was horri

I have been taking crestor for about four years for highly elevated hdl. First 20mg now 10mg and am increasingly concerned that increased lethergy, cognitive impairment - short term memory loss and aphasia as well as chronic muscle ache may be a resu

I have been taking Pariet for over 6 months &amp; just realised I must be suffering side effects...reoccuring Flu symptoms &amp; Rhinitis, occasional leg cramps &amp; awakening with visual disturbances.

I have been using Garasone drops and recently (10 days ago) I have been experiencing vertigo and visual disturbances. I stoped the drops and what should I do now.

VISUAL IMPAIRMENT Clinical Trials and Studies

Treatments might be new drugs or new combinations of drugs, new surgical procedures or devices, or new ways to use existing treatments. The goal of clinical trials is to determine if a new test or treatment works and is safe. Clinical trials can also look at other aspects of care, such as improving the quality of life for people with chronic illnesses. People participate in clinical trials for a variety of reasons. Healthy volunteers say they participate to help others and to contribute to moving science forward. Participants with an illness or disease also participate to help others, but also to possibly receive the newest treatment and to have the additional care and attention from the clinical trial staff.
Rank Status Study
1 Recruiting Abuse Liability of Controlled-Release Oxycodone Formulations
Condition: Substance-Related Disorders
Interventions: Drug: Apo-Oxycodone CR®;   Drug: OxyNEO®;   Drug: OxyContin®;   Drug: Placebo
Outcome Measures: Change from Baseline on Visual Analogue Scale for "Drug Liking" Over 8 Hours After Drug Administration;   Change from Baseline on Visual Analogue Scale for "Drug High" Over 8 Hours After Drug Administration;   Pupil Diameter;   Cmax;   Profile of Mood States (POMS);   Psychomotor Performance;   Visual Analogue Scale for "Any Drug Effects";   Visual Analogue Scale for "Good Effects";   Visual Analogue Scale for "Bad Effects";   Visual Analogue Scale for "Feel Sick";   Visual Analogue Scale for "Nausea";   Visual Analogue Scale for "Sleepy";   Visual Analogue Scale for "Dizzy";   Sedation;   Euphoria;   Dysphoric Changes;   Psychotomimetic Changes;   Somatic Disturbances;   Sensory Disturbances;   Tmax
2 Recruiting Oxycodone Versus Intravenous Morphine for Postoperative Analgesia After Hip Surgery
Condition: Arthroplasty, Replacement, Hip
Interventions: Drug: Standard Care morphine hydrochloride;   Drug: Oxycodone
Outcome Measures: Composite score of complications;   Number of opioid boluses in the post-intervention surveillance room;   Time to obtain a VAS score < 30/100 (from the first administration; minutes);   Length of stay in the post-intervention surveillance room (minutes);   Total dose of opioids during the first 24 hours (mg);   Total number of opioid requestions (patient controlled analgesia = PCA);   Total number of opioid requestions accepted / refused (PCA);   Ramsay score;   Presence / absence of an overdose of morphine/Oxycodone (Ramsay score > 4);   Presence / absence of an overdose of morphine/Oxycodone (Ramsay score> 4);   Presence/absence of complications;   Patient satisfaction, VAS scale;   Pain while at rest at while moving (Visual Analog Scale);   DN4 score;   Length of hospital stay (hours)
3 Recruiting Comparison of the Efficacy of Oral Oxycodone and Oral Codeine in the Treatment of Postcraniotomy Pain
Condition: Postcraniotomy Pain
Interventions: Drug: Oxycodone;   Drug: Codeine
Outcome Measures: To determine the difference in the mean pain VAS scores in the Oxycodone and codeine groups at 24hr.;   To look at the incidence of adverse events in the Oxycodone and codeine groups.
4 Recruiting A Study to Evaluate Efficacy and Safety of Oxycodone/Naloxone Compared to OxyContin in Korean Cancer Patients
Condition: Cancer
Intervention: Drug: Oxycodone and naloxone
Outcome Measures: Assess reduction of pain intensity;   Efficacy parameters including long term safety and efficacy
5 Not yet recruiting Population Pharmacokinetics and Pharmacogenomics of Oral Oxycodone in Pediatric Surgical Patients
Condition: Pediatric Surgical Patient
Intervention: Drug: oral Oxycodone
Outcome Measure: Oxycodone, oxymorphone, noroxymorphone and norOxycodone serum levels
6 Recruiting Safety of Twice Daily Oxycodone Hydrochloride Controlled-release Tablets in Children With Moderate to Severe Malignant and/ or Nonmalignant Pain Requiring Opioids
Condition: Pain
Intervention: Drug: Oxycodone HCl controlled-release tablets
Outcome Measures: The number of participants with adverse events as a measure of safety.;   To characterize the efficacy and provide additional pharmacokinetics (PK) data of Oxycodone hydrochloride controlled-release tablets
7 Unknown  Evaluation of the Efficacy and Tolerability of Etoricoxib Monotherapy Versus Combination Oxycodone-etoricoxib in Moderate to Severe Pain From Chronic Low Back Pain
Condition: Low Back Pain
Interventions: Drug: etoricoxib;   Drug: Oxycodone
Outcome Measures: Proportion of patients achieving a > 30% reduction in avg daily pain intensity at treatment week 4 (Visit 4).;   Proportion of patients achieving a > 50% reduction in avg daily pain intensity at treatment week 5 (visit 4).
8 Recruiting Evaluate The Pharmacokinetics and Safety Of Oxycodone Oral Solution In Pediatric and Adolescent Subjects
Condition: Pain
Intervention: Drug: Oxycodone
Outcome Measures: Cmax of Oxycodone Oral Solution.;   Safety of Oxycodone Oral Solution in Pediatric Patients
9 Not yet recruiting Effects of Food on Oxycodone Pharmacokinetics in Healthy Volunteers
Condition: Healthy
Intervention: Drug: Oxycodone
Outcome Measures: Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - 8)];   Maximum Observed Plasma Concentration (Cmax);   Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast);   Concentration at time 24 hours (C24);   Time to Reach Maximum Observed Plasma Concentration (Tmax);   Plasma Decay Half-Life (t1/2)
10 Unknown  A Comparative Study With Parenteral Oxycodone, Morphine and Dexamethasone in Postoperative Pain in Paediatric Patients
Condition: Post Tonsillectomy Pain
Interventions: Drug: 0,1 mg/kg of Oxycodone;   Drug: Morphine 0,1 mg/kg;   Drug: Dexamethasone 0,5 mg/kg;   Drug: NaCl 0,9%
Outcome Measures: The difference of needed rescue pain medication post operatively;   differences in adverse effects
11 Recruiting An Interventional Study to Assess the Efficacy and Safety of Oxycodone/Naloxone in Korean Patients With Spinal Disorders
Condition: Spinal Disorders Related Pain
Intervention: Drug: Oxycodone/Naloxone
Outcome Measures: 24hr pain intensity score (Numeric rating score: 0 -10);   EuroQol-5 Dimension(EQ-5D);   Overall satisfaction of Physicians and subjects
12 Recruiting Norspan Versus Oxycontin as Postoperative Painkiller to Proximal Extracapsular Fractures of the Femur
Condition: Pain, Postoperative
Interventions: Drug: Buprenorphine;   Drug: Oxycodone
Outcome Measures: Mobilization measured daily using Cumulated Ambulation Score.;   Pain intensity measured daily on a verbal rating scale;   Adverse effects;   Opioid consumption.;   Length of stay in Hospital
13 Not yet recruiting A Comparison of Targinact vs. Oxycodone on Gut Function After Colorectal Surgery
Conditions: Postoperative Pain;   Postoperative Nausea and Vomiting
Interventions: Drug: Targinact;   Drug: Oxycodone;   Procedure: Laparoscopic segmental colectomy
Outcome Measures: Prevalence of postoperative gut dysfunction;   Pain control;   Oral analgesia use;   Pain scores
14 Recruiting Targin Cancer Pain
Conditions: Cancer;   Pain
Interventions: Drug: Oxycodone/Naloxone;   Drug: Oxycodone
Outcome Measures: BFI-Bowel Function Index;   BPI-Brief Pain Index
15 Not yet recruiting A Randomized, Open-label, Multiple-dose, Two-sequence, Two-period Crossover Study to Investigate The Pharmacokinetics Between a GL2907 and Oxycontin CR Tab. 10mg in Healthy Male Volunteers
Condition: Healthy
Interventions: Drug: GL2907;   Drug: Oxycontine CR 10mg
Outcome Measures: Cmax,ss;   AUCτ;   Tmax;   t1/2;   Vz/f;   CL/F;   Cmin,ss;   Cave,ss;   degree og fluctuation;   swing;   R
16 Recruiting Targin for Non-cancer Pain
Condition: Non Cancer Pain
Intervention: Drug: Oxycodone/naloxone prolonged release tablets
Outcome Measures: Bowel function index(BFI) 12 Weeks;   Modified BPI-SF-Average Pain over the last 24 hours
17 Recruiting RCT Comparing the Analgesic Efficacy of 4 Therapeutic Strategies Based on 4 Different Major Opioids (Fentanyl, Oxycodone, Buprenorphine vs Morphine) in Cancer Patients With Moderate/Severe Pain, at the Moment of Starting 3rd Step of WHO Analgesic Ladder.
Conditions: Cancer;   Cancer Pain
Interventions: Drug: Morphine;   Drug: Fentanyl;   Drug: Buprenorphine;   Drug: Oxycodone
Outcome Measures: Proportion of Non-Responder (NR) patients;   Proportion of full-responder
18 Recruiting Effects of Ibudilast on Oxycodone Self-administration in Opioid Abusers
Conditions: Opioid Abuse;   Opioid Dependence
Interventions: Drug: MN-166 (formerly AV411);   Drug: placebo
Outcome Measures: pain intensity;   positive subjective effects to Oxycodone
19 Recruiting Effects of Pioglitazone, a PPARgamma Receptor Agonist, on the Abuse Liability of Oxycodone
Condition: Opioid Abuse
Intervention: Drug: pioglitazone
Outcome Measures: Subjective ratings of drug, mood, and physiological effects;   Analgesic responses using the cold pressor test
20 Recruiting Abuse Potential Study of PF-00345439
Condition: Opioid Users
Interventions: Drug: Capsule;   Drug: PF-00345439;   Drug: Oxycodone
Outcome Measures: Drug Liking: Peak Effect (Emax);   High: Peak Effect (Emax);   Drug Liking: Area Under Effect Curve (AUE) From 0-2 Hours;   High: Area Under Effect Curve (AUE) From 0-2 Hours;   Take Drug Again Effect at 24 Hours;   Overall Drug Liking;   Any Drug Effects: Area Under Drug Effect Curve (AUE) From 0-1 Hour;   Pupillometry: Area Under Effect Curve (AUE) From 0-1 Hour;   Chewing Duration;   Taste: Subjective Experience from Chewing;   Any Drug Effects: Area Under Drug Effect Curve (AUE) From 0-2 Hours;   Any Drug Effects: Area Under Drug Effect Curve (AUE) From 0-3 Hours;   Any Drug Effects: Area Under Drug Effect Curve (AUE) From 0-12 Hours;   Pupillometry: Area Under Effect Curve (AUE) From 0-2 Hours;   Pupillometry: Area Under Effect Curve (AUE) From 0-3 Hours;   Pupillometry: Area Under Effect Curve (AUE) From 0-12 Hours;   High: Area Under Effect Curve (AUE) From 0-1 Hour;   High: Area Under Effect Curve (AUE) From 0-3 Hours;   High: Area Under Effect Curve (AUE) From 0-12 Hours;   Good Drug Effects: Area Under Drug Effect Curve (AUE) From 0-1 Hour;   Good Drug Effects: Area Under Effect Curve (AUE) From 0-2 Hours;   Good Drug Effects: Area Under Effect Curve (AUE) From 0-3 Hours;   Good Drug Effects: Area Under Effect Curve (AUE) From 0-12 Hours;   Bad Drug Effects: Area Under Effect Curve (AUE) From 0-1 Hour;   Bad Drug Effects: Area Under Effect Curve (AUE) From 0-2 Hours;   Bad Drug Effects: Area Under Effect Curve (AUE) From 0-3 Hours;   Bad Drug Effects: Area Under Effect Curve (AUE) From 0-12 Hours;   Feeling Sick: Area Under Effect Curve (AUE) From 0-1 Hour;   Feeling Sick: Area Under Effect Curve (AUE) From 0-2 Hours;   Feeling Sick: Area Under Effect Curve (AUE) From 0-3 Hours;   Feeling Sick: Area Under Effect Curve (AUE) From 0-12 Hours;   Nausea: Area Under Effect Curve (AUE) From 0-1 Hour;   Nausea: Area Under Effect Curve (AUE) From 0-2 Hours;   Nausea: Area Under Effect Curve (AUE) From 0-3 Hours;   Nausea: Area Under Effect Curve (AUE) From 0-12 Hours;   Sleepy: Area Under Effect Curve (AUE) From 0-1 Hour;   Sleepy: Area Under Effect Curve (AUE) From 0-2 Hours;   Sleepy: Area Under Effect Curve (AUE) From 0-3 Hours;   Sleepy: Area Under Effect Curve (AUE) From 0-12 Hour;   Dizzy: Area Under Effect Curve (AUE) From 0-1 Hour;   Dizzy: Area Under Effect Curve (AUE) From 0-2 Hours;   Dizzy: Area Under Effect Curve (AUE) From 0-3 Hours;   Dizzy: Area Under Effect Curve (AUE) From 0-12 Hours;   Bad Effects: Peak Effect (Emax);   Nausea: Peak Effect (Emax);   Feel Sick: Peak Effect (Emax);   Sleepy: Peak Effect (Emax);   Dizzy: Peak Effect (Emax);   Pupillometry: Peak Effect (Emax);   Good Drug Effects: Peak Effect (Emax);   Drug Liking: Area Under Effect Curve (AUE) From 0-1 Hour;   Drug Liking: Area Under Effect Curve (AUE) From 0-3 Hours;   Drug Liking: Area Under Effect Curve (AUE) From 0-12 Hours;   Drug Liking: Time to Maximum (Peak) Effect (TEmax);   High: Time to Maximum (Peak) Effect (TEmax);   Any Drug Effects: Time to Maximum (Peak) Effect (TEmax);   Good Drug Effects: Time to Maximum (Peak) Effect (TEmax);   Bad Drug Effects: Time to Maximum (Peak) Effect (TEmax);   Feel Sick: Time to Maximum (Peak) Effect (TEmax);   Nausea: Time to Maximum (Peak) Effect (TEmax);   Sleepy: Time to Maximum (Peak) Effect (TEmax);   Dizzy: Time to Maximum (Peak) Effect (TEmax);   Pupillometry: Time to Maximum (Peak) Effect (TEmax);   Any Drug Effects: Peak Effect (Emax);   Texture: Subjective Experience from Chewing;   Maximum Observed Plasma Concentration (Cmax);   Time to Reach Maximum Observed Plasma Concentration (Tmax);   Area under the curve (AUC);   Systemic Clearance (CL);   volume of distribution (Vd);   Half-Life (t1/2)